LAWRENCE, Mass., April 28, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today commented on study results presented by the Chronic Disease Research Group (CDRG) showing daily home hemodialysis with the NxStage System One is associated with reduced mortality and higher survival estimates for patients when compared with conventional thrice-weekly therapy. The retrospective cohort study examines the mortality and three-year survival rates of 1,873 daily home hemodialysis (DHHD) patients using the NxStage System One between 2005 and 2007, to a matched cohort of 9,365 in-center hemodialysis patients from the United States Renal Data System (USRDS) database. CDRG is a nonprofit division of the Minneapolis Medical Research Foundation committed to investigating chronic illness to improve public health, including leveraging USRDS data to conduct studies.
The study, "Relative Mortality in Daily Home and Matched, Thrice-Weekly In-Center Hemodialysis Patients," conducted by CDRG was presented at this week's National Kidney Foundation 2011 Spring Clinical Meeting in Las Vegas.
"This is the first study of its kind to carefully match the daily home hemodialysis patient population with comparable in-center dialysis patients based on variables such as comorbidity and severity of disease, determining the impact on mortality," said Dr. Allan Collins, professor of medicine, University of Minnesota, and director, Chronic Disease Research Group. "Results show a reduction in mortality for daily home hemodialysis patients consistent with recently published National Institutes of Health data on frequent home dialysis versus in-center therapy, though additional studies are needed to assess patient hospitalization risk and type of hospitalization."
Researchers compared daily home hemodialysis patient data with the